[Future perspectives of ulcer therapy].
Anti-ulcer drugs are amongst the world's most successful pharmaceutical products. Whilst the market for histamine H2 antagonists is maturing, that for proton pump inhibitors looks set to expand considerably during the 1990s. Indeed, by analogy with anti-hypertensive therapy, enzyme inhibitors could eventually supersede receptor antagonists for the treatment of acid-related diseases. Whether a third major cycle of innovative drugs will follow the cimetidine and omeprazole led discoveries of the 1970s and 80s is more difficult to predict given the efficacy of current agents, the declining incidence of ulcer disease, and the need to focus resources in areas of clinical need such as gastrointestinal cancer. Therapy targetted against Helicobacter pylori represents the most attractive option for developing the next generation of anti-ulcer drugs. A major initiative to eradicate H. pylori would be justified if such therapy also had utility in gastric cancer.
Garner
A
A
Department of Pharmacology, Faculty of Medicine and Health Sciences, UAE University, Al Ain, United Arab Emirates.
D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001729:Bismuth / Q000627:therapeutic use; D005544:Forecasting; D016481:Helicobacter Infections / Q000188:drug therapy; D016480:Helicobacter pylori; D006801:Humans; D010437:Peptic Ulcer / Q000188:drug therapy*
D000897:Anti-Ulcer Agents; D001729:Bismuth
Zukunftsperspektiven der Ulkustherapie.